Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 2;22(19):7656-7661.
doi: 10.1021/acs.orglett.0c02848. Epub 2020 Sep 15.

Expanding Access to Remdesivir via an Improved Pyrrolotriazine Synthesis: Supply Centered Synthesis

Affiliations

Expanding Access to Remdesivir via an Improved Pyrrolotriazine Synthesis: Supply Centered Synthesis

Dinesh J Paymode et al. Org Lett. .

Abstract

Pyrrolotriazine 1 is an important precursor to remdesivir. Initial results toward an efficient synthesis are disclosed consisting of sequential cyanation, amination, and triazine formation beginning from pyrrole. This route makes use of highly abundant, commoditized raw material inputs. The yield of triazine was doubled from 31% to 59%, and the synthetic step count was reduced from 4 to 2. These efforts help to secure the remdesivir supply chain.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
An atom economic route to triazine from abundant chemicals.
Figure 2
Figure 2
A simple one-pot cyanation.
Figure 3
Figure 3
Clean amination of pyrrole from bleach and ammonia under highly dilute conditions.
Figure 4
Figure 4
(a) Lower equivalents of chloramine can be used at lower loadings of NaH. (b) Addition of NH2Cl in multiple charges with subsequent solvent recycle increases throughput and decreases solvent consumption.
Figure 5
Figure 5
Steady state operation of chloramine CSTR and schematic for chloramine generator.
Figure 6
Figure 6
One-pot triazine synthesis from cyanopyrrole 4.

References

    1. Mullin R.COVID-19 is reshaping the pharmaceutical supply chain, Chem. Eng. News, 2020, 98.
    2. Mullin R.Bringing drug production back to the US. Chem. Eng. News, 2020, 98.
    3. Woodcock J.; Safeguarding Pharmaceutical Supply Chains in a Global Economy; U.S. Food and Drug Administration. https://www.fda.gov/news-events/congressional-testimony/safeguarding-pha... (Accessed July 10, 2020).
    1. For examples see Gilead company statements:

    2. An Update on COVID-19 from our Chairman & CEO; Gilead Sciences, Inc. https://stories.gilead.com//articles/an-update-on-covid-19-from-our-chai... (Accessed July 1, 2020).
    3. An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences; Gilead Sciences, Inc. https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/a... (Accessed July 1, 2020).
    4. Trump Administration Secures New Supplies of Remdesivir for the United States; U.S. Department of Health and Human Services. https://www.hhs.gov/about/news/2020/06/29/trump-administration-secures-n... (Accessed July 10, 2020).
    1. Siegel D.; Hui H. C.; Doerffler E.; Clarke M. O.; Chun K.; Zhang L.; Neville S.; Carra E.; Lew W.; Ross B.; Wang Q.; Wolfe L.; Jordan R.; Soloveva V.; Knox J.; Perry J.; Perron M.; Stray K. M.; Barauskas O.; Feng J. Y.; Xu Y.; Lee G.; Rheingold A. L.; Ray A. S.; Bannister R.; Strickley R.; Swaminathan S.; Lee W. A.; Bavari S.; Cihlar T.; Lo M. K.; Warren T. K.; Mackman R. L. J. Med. Chem. 2017, 60, 1648–1661. 10.1021/acs.jmedchem.6b01594. - DOI - PubMed
    2. De Savi C.; Hughes D. L.; Kvaerno L. Org. Process Res. Dev. 2020, 24, 940–976. 10.1021/acs.oprd.0c00233. - DOI - PubMed
    3. Vieira T.; Stevens A. C.; Chtchemelinine A.; Gao D.; Badalov P.; Heumann L.. Org. Process Res. Dev. 2020, ASAP.10.1021/acs.oprd.0c00172. - DOI - PubMed
    1. Snead D. R.; McQuade D. T.; Ahmad S.; Krack R.; Stringham R. W.; Burns J. M.; Abdiaj I.; Gopalsamuthiram V.; Nelson R. C.; Gupton B. F. Org. Process Res. Dev. 2020, 24, 1194–1198. 10.1021/acs.oprd.0c00083. - DOI - PMC - PubMed
    2. Kashinath K.; Snead D. R.; Burns J. M.; Stringham R. W.; Gupton B. F.; McQuade D. T. M.. Org. Process Res. Dev. 2020, ASAP.10.1021/acs.oprd.0c00145. - DOI - PMC - PubMed
    1. Dixon J. A.; Phillips B.; Achebe F.; Kluender H. C. E.; Newcom J.; Parcella K.; Magnuson S.; Hong Z.; Zhang Z.; Liu Z.; Khire U.; Wang L.; Michels M.; Chandler B.; O’Connor S.. US 8143393, 2006.
    2. O’Connor S.; Dumas J.; Lee W.; Dixon J.; Cantin D.; Gunn D.; Burke J.; Phillips B.; Lowe D.; Shelekhin T.; Wang G.; Ma X.; Ying S.; McClure A.; Achebe F.; Lobell M.; Ehrgott F.; Iwuagwu C.; Parcella K.. US 8431695, 2006.

LinkOut - more resources